Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing

Transfusion

Volumn 48, Issue 12, 2008, Pages 2540-2548

  Contreras, Ana M ^a   Tornero Romo, Claudia M ^b   Toribio, José G ^b   Celis, Alfredo ^b   Orozco Hernández, Axel ^b   Rivera, P Kristian ^b   Méndez, Claudia ^b   Hernández Lugo, M Isabel ^b   Olivares, Laura ^b   Alvarado, Martha A ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; GOLD STANDARD; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; MALE; RNA ANALYSIS; VIREMIA; VIRUS DETECTION;

ADULT; FALSE POSITIVE REACTIONS; FEMALE; HEPATITIS C ANTIBODIES; HUMANS; MALE;

EID: 57249086419     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01886.x     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep 1991 40 (No. RR-4 1 17.
2. World Health Organization. Blood Transfusion Safety. Testing and processing. Geneva : WHO. [cite 2007 Sep]. Available from: http://www.who.int/ bloodsafety/testing_processing/en/
3. Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994 343 : 853 4.
4. Goffin E, Pirson Y, Cornu C, Jadoul M, van Ypersele de Strihou C. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994 343 : 854.
5. Galel SA, Strong DM, Tegtmeier GE, Holland PV, Kuramoto IK, Kemper M, Pietrelli L, Gallarda J. Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays. Transfusion 2002 42 : 1507 13.
6. Tobler LH, Stramer SL, Lee SR, Masecar BL, Peterson JE, Davis EA, Andrews WE, Brodsky JP, Kleinman SH, Phelps BH, Busch MP. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. Transfusion 2003 43 : 1452 9.
7. Contreras AM, Tinoco E, Celis A, Novelo B, Romero P, Carrada E, Jiménez-Méndez R. Hepatitis C antibody intraassay correlation: is retest in duplicate necessary? Transfusion 2007 47 : 1686 90.
8. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003 52 (RR-3 1 13, 15; quiz CE1-4.
9. Contreras AM. Hepatitis C antibody: true or false? New diagnosis strategies. Rev Invest Clin 2006 58 : 153 60.
10. Bar-Shany S, Green MS, Shinar E. False positive test for anti-hepatitis C antibodies and the problem of notifying blood donors. Int J Epidemiol 1996 25 : 674 8.
11. Schröter M, Feucht HH, Schäfer P, Zöllner B, Polywka S, Laufs R. Definition of false-positive reactions in screening for hepatitis C virus antibodies. J Clin Microbiol 1999 37 : 233 4.
12. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998 27 : 1700 2.
13. Carithers RL, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000 20 : 159 71.
14. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002 36 : S65 73.
15. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002 36 : S3 20. Available from: http://www3.interscience.wiley.com/cgi-bin/fulltext/106597945/ PDFSTART
16. Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006 3 : 35 40.
17. Contreras AM, Tornero-Romo C, Orozco-Hernández A, Hernández-Lugo MI, Romero MV, Celis A. Rediscovering hepatitis C antibody: new screening and diagnosis strategies. Gac Med Mex 2007 143 : S3 12.
18. Dufour DR, Talastas M, Fernández MDA, Harris B. Chemiluminescence assay improves specificity of hepatitis C antibody detection. Clin Chem 2003 49 : 940 4.
19. Oethinger M, Mayo DR, Falcone JA, Barua PK, Griffith BP. Efficiency of the Ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios. J Clin Microbiol 2005 43 : 2477 80.
20. Food and Drug Administration. CBER Guidances Guidelines Points to Consider. Lookback for hepatitis C virus (HCV): product quarantine consignee notification, further testing, product disposition, and notification of transfusion recipients based on donor test results indicating infection with HCV. Rockville (MD) : FDA. [cite 2007 Sep]. Available from: http://www.fda.gov/ cber/guidelines.htm
21. Tobler LH, Tegtmeier G, Stramer SL, Quan S, Dockter J, Giachetti C, Busch MP. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000 40 : 15 24.
22. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C and influenza A virus determinant-specific cytotoxic T cells. J Virol 2001 75 : 11392 400.
23. Nixon RR, Smith SA, Johnson RL, Pillers DA. Misleading hepatitis C serology following administration of intravenous immunoglobulin. Am J Clin Pathol 1994 101 : 327 8.
24. Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 2004 44 : 349 58.
25. Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, Sayada C, Duval J, Dhumeaux D. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996 34 : 80 3.
26. Kondili LA, Chionne P, Costantino A, Vilano U, Lo Noce C, Panozzo F, Mele A, Giampaoli S, Rapicetta M. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002 50 : 693 6.
27. Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion 2006 46 : 695 702.
28. Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003 43 : 1433 41.
29. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004 141 : 715 7.
30. Tynell E, Norda R, Ekermo B, Sanner M, Andersson S, Björkman A. False-reactive microbiologic screening test results in Swedish blood donors - how big is the problem? A survey among blood centers and deferred donors. Transfusion 2007 47 : 80 9.
31. Conry-Cantilena C, vanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, Kaslow R, Ness P, Alter HJ. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996 331 : 1691 6.
32. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ. Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 2000 31 : 756 62.